Myriad Genetics, Inc. (MYGN)
4.35
+0.20
(+4.82%)
USD |
NASDAQ |
Oct 15, 16:00
4.345
0.00 (0.00%)
After-Hours: 20:00
Myriad Genetics Research and Development Expense (Quarterly) : 25.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.00M |
| March 31, 2026 | 27.10M |
| December 31, 2025 | 25.50M |
| September 30, 2025 | 28.20M |
| June 30, 2025 | 25.60M |
| March 31, 2025 | 27.50M |
| December 31, 2024 | 29.70M |
| September 30, 2024 | 28.50M |
| June 30, 2024 | 27.10M |
| March 31, 2024 | 24.90M |
| December 31, 2023 | 21.00M |
| September 30, 2023 | 24.00M |
| June 30, 2023 | 21.20M |
| March 31, 2023 | 22.50M |
| December 31, 2022 | 23.40M |
| September 30, 2022 | 20.50M |
| June 30, 2022 | 20.30M |
| March 31, 2022 | 21.20M |
| December 31, 2021 | 16.60M |
| September 30, 2021 | 18.80M |
| June 30, 2021 | 19.50M |
| March 31, 2021 | 23.10M |
| June 30, 2020 | 17.40M |
| March 31, 2020 | 19.70M |
| December 31, 2019 | 18.80M |
| Date | Value |
|---|---|
| September 30, 2019 | 21.30M |
| June 30, 2019 | 20.90M |
| March 31, 2019 | 21.40M |
| December 31, 2018 | 21.80M |
| September 30, 2018 | 21.10M |
| June 30, 2018 | 17.70M |
| March 31, 2018 | 18.50M |
| December 31, 2017 | 16.80M |
| September 30, 2017 | 17.80M |
| June 30, 2017 | 18.80M |
| March 31, 2017 | 17.60M |
| December 31, 2016 | 18.60M |
| September 30, 2016 | 19.40M |
| June 30, 2016 | 19.50M |
| March 31, 2016 | 17.20M |
| December 31, 2015 | 16.70M |
| September 30, 2015 | 17.20M |
| June 30, 2015 | 18.70M |
| March 31, 2015 | 16.67M |
| December 31, 2014 | 17.50M |
| September 30, 2014 | 22.61M |
| June 30, 2014 | 20.19M |
| March 31, 2014 | 13.40M |
| December 31, 2013 | 17.09M |
| September 30, 2013 | 16.29M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Natera, Inc. | 228.07M |
| Sera Prognostics, Inc. | 3.331M |
| BioRestorative Therapies, Inc. | 1.926M |
| CareDx, Inc. | 22.38M |
| Exagen, Inc. | 1.426M |